SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to excitement over its strategic collaboration with Meta and others to provide nuclear power for data centers, alongside a new U.S. Department of Energy agreement for a radioisotope pilot facility. The community is actively discussing the stock's potential as a key player in powering AI and achieving U.S. energy independence, with many anticipating further developments from an upcoming congressional hearing on nuclear energy and fuel allocation amidst ongoing debate between bullish investors and those concerned about insider selling and pre-revenue status.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is experiencing significant upward momentum driven by news of potential government action to acquire $200 billion in mortgage bonds, aiming to lower interest rates. The community is highly optimistic, anticipating a robust recovery in the housing market and a surge in transaction volumes, which could benefit Opendoor's business model and potentially trigger a short squeeze. This renewed focus on housing affordability is a major talking point among investors.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending following news of major nuclear energy deals aimed at powering its expanding AI data centers, a strategic move generating significant community excitement regarding the future of its AI infrastructure. While this signals aggressive investment in AI, some investors remain divided, expressing frustration with recent stock performance amidst regulatory reviews, such as the Manus AI acquisition, and high demand for its Ray-Ban smart glasses delaying international expansion. The market keenly watches how these initiatives will impact Meta's trajectory ahead of its upcoming earnings report.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

The nuclear power sector, particularly Small Modular Reactors (SMRs) like NuScale Power, is trending amidst increasing energy demands from AI data centers and anticipated government efforts to streamline nuclear permits. The community is actively discussing the potential for upcoming major contract announcements, recent insider buying, and NuScale's unique advantage as the only company with an NRC-approved SMR design.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, Sunset, and Asset Closure. The Retail segment sells electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Sunset segment includes generation plants with announced retirement plans. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Vistra Corp is trending following reports of its strategic $4 billion acquisition of Cogentrix Energy's natural gas facilities, a move designed to meet the escalating electricity demand from AI and data centers. The community is actively debating whether recent significant price movements are due to profit-taking or market manipulation, despite the acquisition bolstering Vistra's long-term position in the power sector. The broader conversation centers on Vistra's role in addressing the critical power needs for rapidly expanding AI infrastructure.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending due to overwhelmingly positive feedback from its Type B FDA meeting, confirming a clear path for its lead drug, sonelokimab, towards a Biologic License Application in hidradenitis suppurativa without additional trials. This regulatory clarity has significantly de-risked the asset, fueling community discussions around strong analyst upgrades and rekindling fervent speculation about a potential acquisition from major pharma, with many anticipating a substantial revaluation towards previous highs.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is a primary discussion point following reports its subsidiary, Airobotics, secured a major contract for Israel's "Drone Hives" border security, amplified by broader expectations of increased defense spending. The community is split, with many anticipating significant upside in the burgeoning drone and autonomous systems sector, while others raise concerns about valuation and the specifics of defense contracts.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy is trending after securing a significant agreement with the U.S. Department of Energy for Project TETRA, a crucial step towards developing its Integral Molten Salt Reactor pilot plant. The community is actively discussing this as a major de-risking catalyst, drawing comparisons to peers like $OKLO, and emphasizing the immense demand for advanced nuclear solutions, particularly for AI data centers. Many believe this Generation IV technology, coupled with federal fast-track initiatives, positions IMSR for substantial long-term growth within the burgeoning nuclear energy sector.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is trending following the completed Renergen acquisition, which integrates helium and LNG production, and an 'Overweight' analyst rating from Cantor Fitzgerald. The community views these developments as key steps differentiating ASPI in the high-growth nuclear and materials sector, particularly for its potential in HALEU for advanced reactors and silicon-28 for AI computing. Discussions highlight the company's strategic positioning within the broader 'atomic renaissance' amidst anticipation of future revenue streams.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>JNJ agreed to drug discounts and tariff exemptions under a White House deal.</li><li>The agreement builds on its existing $55 billion U.S. manufacturing and R&amp;D plan.</li><li>New facilities add to projects already underway in North Carolina and Pennsylvania.</li></ul><p>Johnson &amp; Johnson (JNJ) said on Thursday it has reached a voluntary agreement with the U.S. government to expand access to medicines, lower drug costs for American patients, and secure exemptions from U.S. tariffs on its pharmaceutical products, while advancing its domestic manufacturing plans.</p><h2 class="st-heading-2"><strong>Drug Pricing And Tariff Exemptions</strong></h2><p>As part of the deal, JNJ will allow Americans to buy medicines at significantly discounted rates through TrumpRx.gov, a government-backed direct-to-patient platform. The company will also provide U.S. Medicaid programs access to medicines at prices comparable to those in other developed countries.</p><p>The deal grants JNJ’s pharmaceutical products exemptions from U.S. tariffs and aligns with the administration’s “most-favored-nation” pricing framework.</p><p>“Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” CEO Joaquin Duato said in a statement.&nbsp;</p><h2 class="st-heading-2"><strong>US Manufacturing Commitments</strong></h2><p>JNJ said the agreement builds on its previously announced $55 billion U.S. investment plan through early 2029, which focuses on expanding domestic manufacturing, research and development, and technology.&nbsp;</p><p>As part of the plan, the company announced two additional U.S. manufacturing facilities, including a cell therapy site in Pennsylvania and a drug product manufacturing facility in North Carolina. Construction is already underway at the company’s $2 billion biologics facility in Wilson, North Carolina, a project expected to support around 5,000 manufacturing and construction jobs.&nbsp;</p><p>Separately, JNJ has committed $2 billion over the next 10 years to a biopharmaceutical site in Holly Springs, North Carolina, which is expected to create about 120 jobs. The company said it expects to announce further U.S. investments later this year.</p><h2 class="st-heading-2"><strong>White House Drug Deals Expand</strong></h2><p>The announcement follows&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-strikes-new-drug-price-deals-with-roche-novartis-merck-and-other-pharma-giants/cLe0duBREtP">similar agreements struck last month</a> between the White House and other major drugmakers, including Amgen, Bristol Myers Squibb, Pfizer, Gilead Sciences, GSK, Merck, Novartis, Roche and Sanofi.</p><p>The deals require steep discounts through TrumpRx, most-favored-nation pricing for Medicaid, expanded U.S. manufacturing, and restrictions on stockpiling drugs to avoid tariffs.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment was ‘bearish’ amid ‘high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/jnj_ss_png_1d85f7828a.webp" alt="jnj ss.png" width="967" height="142"><figcaption>JNJ sentiment and message volume as of January 8| Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/JNJ">JNJ’s stock</a> has risen 49% over the past 12 months.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, a Johnson & Johnson logo seen displayed on a monitor. (Photo Illustration by Valera Golovniov/SOPA Images/LightRocket via Getty Images)

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs 

The company will also provide U.S. Medicaid programs access to medicines at prices comparable to those in other developed countries.

Equity

Top Analyst Reports for Johnson & Johnson, Caterpillar and Qualcomm

JNJ is leaning on Innovative Medicine growth and MedTech momentum to offset the Stelara patent cliff as it heads into 2026.

Healthcare Stocks To Keep An Eye On - January 8th

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Aclarion, and Hims & Hers Health are the five Healthcare stocks to watch today, according to MarketBeat's stock screener tool. As it...

See Which Of The Latest 13F Filers Holds JNJ

At Holdings Channel, we have reviewed the latest batch of the 23 most recent 13F filings for the 12/31/2025 reporting period, and noticed that Johnson & Johnson (Symbol: JNJ) was held by 20 of these...

J&J's Innovative Medicine Segment in Q4: Here's What to Watch

JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.

JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus

J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance the drug into phase III.

Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline

AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.

Johnson & Johnson Submits OTTAVA Robotic Surgical System to the U.S. Food and Drug Administration

Johnson & Johnson today announced that the company has submitted the OTTAVA Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification...

Davis Capital Management Acquires New Shares in Johnson & Johnson $JNJ

Davis Capital Management acquired a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the...

Asset Management One Co. Ltd. Buys 47,524 Shares of Johnson & Johnson $JNJ

Asset Management One Co. Ltd. grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The...

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$2.51	--	--	N/A
Q3 '25	$2.76	$2.80	1.54%	BEAT
Q2 '25	$2.68	$2.77	3.29%	BEAT
Q1 '25	$2.58	$2.77	7.34%	BEAT
Q4 '24	$1.99	$2.04	2.43%	BEAT

JNJ
Johnson & Johnson

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest JNJ News

JNJJohnson & Johnson